Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
3.030
+0.150 (5.21%)
At close: Jun 26, 2026, 4:00 PM EDT
3.070
+0.040 (1.32%)
After-hours: Jun 26, 2026, 5:06 PM EDT
Agenus Employees
Agenus had 81 employees as of December 31, 2025. The number of employees decreased by 235 or -74.37% compared to the previous year.
Employees
81
Change (1Y)
-235
Growth (1Y)
-74.37%
Revenue / Employee
$1,529,210
Profits / Employee
$794,951
Market Cap
126.18M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 81 | -235 | -74.37% |
| Dec 31, 2024 | 316 | -73 | -18.77% |
| Dec 31, 2023 | 389 | -144 | -27.02% |
| Dec 31, 2022 | 533 | 92 | 20.86% |
| Dec 31, 2021 | 441 | 82 | 22.84% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fractyl Health | 100 |
| enGene Therapeutics | 82 |
| PepGen | 56 |
| Jyong Biotech | 27 |
| Genelux | 26 |
| Spero Therapeutics | 25 |
| Coya Therapeutics | 8 |
| Aldeyra Therapeutics | 7 |
AGEN News
- 1 day ago - Agenus announces three-year survival data from Phase 1b BOT+BAL study - TheFly
- 1 day ago - Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026 - Business Wire
- 10 days ago - Agenus Transcript: AGM 2026 - Transcripts
- 24 days ago - Agenus Announces Virtual 2026 Annual Shareholders Meeting - Business Wire
- 5 weeks ago - Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC - Business Wire
- 5 weeks ago - Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026 - Business Wire
- 6 weeks ago - Agenus announces publication of Phase 1b BOT+BAL data - TheFly
- 6 weeks ago - Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer - Business Wire